Isomorphic Labs and Johnson & Johnson's Janssen unit announced a cross-modality AI drug-design collaboration on January 20, 2026, extending Isomorphic's platform beyond small molecules into biologics, peptides, and molecular glues aimed at historically undruggable targets.
Isomorphic Labs, the AlphaFold-derived drug-design spinoff of Google DeepMind, raised $2.1 billion on May 13, 2026, the second-largest biotech fundraise ever, betting investors that its AI platform can move from protein prediction to an actual clinical pipeline.
Eli Lilly signed a research and licensing deal worth up to $2.75 billion with Insilico Medicine on March 30, 2026, handing the AI-native biotech's generative drug-design platform a shot at filling Lilly's pipeline with molecules no human chemist screened.
Bayesian Health's TREWS platform, developed at Johns Hopkins, received the first-ever FDA clearance for a continuous AI sepsis monitor on May 12, 2026, after a study found it cut mortality 18% when clinicians acted on its alerts.
The FDA's April 2, 2026 warning letter to Purolea Cosmetics Lab is the agency's first enforcement action to explicitly cite inappropriate AI use, after the company let AI agents draft manufacturing records without human review.
The FDA cleared Anumana's ECG-AI algorithm on April 8, 2026, the first tool authorized to flag cardiac amyloidosis from a standard 12-lead ECG, validated across 25,525 patients with 78.9% sensitivity and 91.2% specificity.
Mercy hospitals in Missouri and Arkansas are piloting an ambient AI tool built into Microsoft Dragon Copilot that documents nursing care by listening in—one nurse says it gave her two hours back in a single shift.
A new UPMC and KLAS Research survey finds 93% of health systems have deployed third-party AI, but only 44% have a dedicated environment to test it—exposing a widening gap between adoption and governance.
Sweden's 105,000-woman MASAI trial found AI-supported mammography reduced aggressive interval cancers, while a $16 million U.S. trial called PRISM now tests the same question nationwide.
Withings' Body Scan 2, on sale in the US since July 2026 for $599.95, reads more than 90 biomarkers to flag hypertension, pre-diabetes and heart rhythm problems, part of a broader company push into reimbursed clinical care.